What patents cover Elfabrio (efgartigimod alfa) and who owns them?
“Elfabrio” is the brand name for efgartigimod alfa. Patents for a specific drug are typically tied to the active ingredient, manufacturing process, and formulation/use claims, and ownership depends on the assignee listed in the patent documents for each jurisdiction (for example, the U.S., Europe, and other countries).
However, no patent numbers, jurisdictions, or assignee details were provided in your request, so I can’t identify the exact Elfabrio patent(s) you mean.
Which “Elfabrio patent” are you looking for (drug substance, process, or method of use)?
People usually search “Elfabrio patent” for one of these:
- patents on the antibody molecule/active ingredient (drug substance),
- patents on making the biologic (manufacturing process),
- patents covering a specific treatment claim (method of use, dosing regimen),
- regulatory exclusivity (which is not the same as a patent, but often searched alongside it).
If you tell me the country/region (e.g., U.S. or EU) and what kind of patent you mean, I can narrow to the right documents.
When does Elfabrio’s protection expire (patent vs exclusivity)?
Patent expiry depends on:
- the filing and priority dates in each jurisdiction,
- adjustments or extensions (if any) granted locally,
- whether there are multiple patents with different end dates,
- whether data exclusivity and marketing exclusivity apply separately from patents.
Without the specific patent numbers or jurisdiction, I can’t provide a reliable expiry date.
Can biosimilars enter before Elfabrio’s patents expire?
For biologics, biosimilar entry is constrained by:
- patent status (and whether any patents are listed for the reference product in the relevant regulatory framework),
- regulatory exclusivity periods,
- litigation or stays tied to challenge outcomes.
A concrete answer requires knowing which patents are asserted/listed and in which jurisdiction.
What I need from you to give the exact Elfabrio patent details
Reply with any one of the following, and I’ll map it to the correct patent set and provide expiration context:
- the jurisdiction (U.S., EU, UK, etc.),
- a patent number or publication number you saw,
- the assignee/company name you’re referring to,
- whether you mean “the main patent,” “the expiration date,” or “the key blocking patents.”
If you share what you already have (even a screenshot text like “US…/EP…”), I’ll take it from there.